Shorla Oncology develops targeted therapies using proprietary drug formulations specifically designed for women's and pediatric cancers, enhancing treatment efficacy in these populations. The company provides life-saving therapeutic options for patients with limited alternatives in underserved cancer demographics.
Funding
$48.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer treatments are not specifically formulated for women's and pediatric cancers, leading to potential inefficacy or increased toxicity in these vulnerable populations. Existing treatments may also be limited in availability or inadequate for the unique needs of these patient groups.
Solution
Shorla Oncology develops and commercializes oncology drugs focused on underserved cancer demographics, particularly women and children. The company reformulates existing cancer treatments to improve their efficacy, accessibility, and safety for these specific populations. Shorla's portfolio includes accessible, affordable, and life-changing treatments, addressing critical gaps in cancer care. Their product development encompasses thought leaders, clinicians, scientists, and commercial strategists with extensive experience in drug development and commercialization of niche cancer treatments.
Target Audience
The primary target audience includes oncologists, pediatric oncologists, and hospitals treating women and children with cancer, as well as patients with specific cancers and autoimmune diseases.
Features
- Reformulated oncology drugs tailored for women's and pediatric cancers
- Focus on indications with limited or inadequate existing treatments
- JYLAMVO™ (methotrexate) for pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) and acute lymphoblastic leukemia (ALL)
- IMKELDI (imatinib mesylate) oral solution for certain forms of leukemia and other cancers
- TEPYLUTE, a ready-to-dilute formulation of thiotepa, for breast and ovarian adenocarcinomas
- Nelarabine Injection
- Pipeline products: SH-105, SH-110, SH-201